When we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.
Once released from the cell, CRP becomes extracellular CIRP or ECIRP, where it then acts as a damp by enhancing the release of cytokines and chemokines, and amplifying the inflammatory cascade.
Remarkably, in the same model under the same conditions, there was 100% survival for CRP knockout pups subjected to neck, whereas the survival was only 65% for wild type pups.
Once released from the cell, extracellular CIRP acts as a DAMP by enhancing the release of cytokines and chemokines and amplifying the inflammatory cascade
MOP3-treated pups had significantly reduced fluorescence intensity indicating protection of the intestinal barrier compared to vehicle-treated NEC pups
Dr. Colleen Nofi - Best of the Best in Pediatric Surgery 2025
▶Ep 63 · 0:39
quoteNecrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.↗
▶Ep 63 · 0:39
clinicalNecrotizing enterocolitis is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by complex pathways that are not completely understood↗
▶Ep 63 · 0:52
clinicalNEC has limited treatment options and an unacceptably high morbidity and mortality risk↗
▶Ep 63 · 1:06
clinicalUnder biologic conditions, CIRP is found inside the cell where it acts as an RNA chaperone protein↗
▶Ep 63 · 1:12
clinicalIn states of cellular stress such as sepsis, CIRP escapes outside the cell↗
▶Ep 63 · 1:19
quoteOnce released from the cell, CRP becomes extracellular CIRP or ECIRP, where it then acts as a damp by enhancing the release of cytokines and chemokines, and amplifying the inflammatory cascade.↗
▶Ep 63 · 1:19
clinicalOnce released from the cell, extracellular CIRP acts as a DAMP by enhancing the release of cytokines and chemokines and amplifying the inflammatory cascade↗
▶Ep 63 · 1:33
clinicalMOP3 (MFGE8 derived oligopeptide 3) is an eCIRP scavenging peptide that removes eCIRP from circulation to reduce inflammation↗
▶Ep 63 · 2:30
clinicalCIRP knockout protected pups from NEC severity with preservation of intestinal villi architecture↗
▶Ep 63 · 2:59
clinicalCIRP knockout mice subjected to NEC showed reduced intestinal inflammation as measured by mRNA levels of IL-6 and TNF-alpha in the small bowel↗
▶Ep 63 · 3:36
clinicalCIRP knockout pups had reduced fluorescent dextran leakage indicating preserved intestinal barrier function compared to wild-type NEC pups↗
▶Ep 63 · 3:57
quoteRemarkably, in the same model under the same conditions, there was 100% survival for CRP knockout pups subjected to neck, whereas the survival was only 65% for wild type pups.↗
▶Ep 63 · 3:57
clinicalCIRP knockout pups subjected to NEC had 100% survival whereas wild-type pups had only 65% survival in the same model under the same conditions↗
▶Ep 63 · 4:18
clinicalMOP3 treatment reduced circulating eCIRP levels in NEC pups compared to vehicle↗
▶Ep 63 · 4:27
clinicalReduction in eCIRP with MOP3 treatment correlated with reduction in systemic inflammatory markers including IL-6 and TNF-alpha↗
▶Ep 63 · 4:37
clinicalMOP3 treatment protected against NEC severity with preservation of intestinal villi↗
▶Ep 63 · 4:55
clinicalMOP3 treatment reduced intestinal inflammation in NEC as measured by mRNA levels of IL-6 and TNF-alpha↗
▶Ep 63 · 5:05
clinicalMOP3-treated pups had significantly reduced fluorescence intensity indicating protection of the intestinal barrier compared to vehicle-treated NEC pups↗
▶Ep 63 · 5:22
clinicalMurine pups subjected to NEC and treated with MOP3 had 80% survival compared to only 50% survival in vehicle-treated pups↗
▶Ep 63 · 5:22
quoteWhen we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.↗
▶Ep 63 · 5:42
clinicalMOP3 protects against NEC pathogenesis by scavenging eCIRP and preventing deleterious downstream impacts↗
▶Ep 63 · 5:42
clinicaleCIRP exacerbates NEC pathogenesis by increasing inflammation and intestinal injury↗
▶Ep 63 · 6:53
clinicalMOP3 is effective in other models of ischemia-reperfusion injury in the gut↗
▶Ep 63 · 7:00
clinicalThe therapeutic benefit of MOP3 is not at the same level as complete CIRP knockdown↗
▶Ep 63 · 7:34
clinicalThe murine NEC model uses a 4-day protocol with continuous stressors including LPS, formula gavage, and hypoxia↗
▶Ep 63 · 7:49
clinicalMOP3 treatment was administered once per day at the beginning of the model, ongoing with the NEC insult↗
Colleen's statements about Intestinal Rehab26 statements
Dr. Colleen Nofi - Best of the Best in Pediatric Surgery 2025
▶Ep 94 · 0:39
quoteNecrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.↗
▶Ep 94 · 0:39
clinicalNecrotizing enterocolitis is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by complex pathways that are not completely understood↗
▶Ep 94 · 0:52
clinicalNEC has limited treatment options and an unacceptably high morbidity and mortality risk↗
▶Ep 94 · 1:06
clinicalUnder biologic conditions, CIRP is found inside the cell where it acts as an RNA chaperone protein↗
▶Ep 94 · 1:12
clinicalIn states of cellular stress such as sepsis, CIRP escapes outside the cell↗
▶Ep 94 · 1:19
clinicalOnce released from the cell, extracellular CIRP acts as a DAMP by enhancing the release of cytokines and chemokines and amplifying the inflammatory cascade↗
▶Ep 94 · 1:19
quoteOnce released from the cell, CRP becomes extracellular CIRP or ECIRP, where it then acts as a damp by enhancing the release of cytokines and chemokines, and amplifying the inflammatory cascade.↗
▶Ep 94 · 1:33
clinicalMOP3 (MFGE8 derived oligopeptide 3) is an eCIRP scavenging peptide that removes eCIRP from circulation to reduce inflammation↗
▶Ep 94 · 2:30
clinicalCIRP knockout protected pups from NEC severity with preservation of intestinal villi architecture↗
▶Ep 94 · 2:59
clinicalCIRP knockout mice subjected to NEC showed reduced intestinal inflammation as measured by mRNA levels of IL-6 and TNF-alpha in the small bowel↗
▶Ep 94 · 3:36
clinicalCIRP knockout pups had reduced fluorescent dextran leakage indicating preserved intestinal barrier function compared to wild-type NEC pups↗
▶Ep 94 · 3:57
clinicalCIRP knockout pups subjected to NEC had 100% survival whereas wild-type pups had only 65% survival in the same model under the same conditions↗
▶Ep 94 · 3:57
quoteRemarkably, in the same model under the same conditions, there was 100% survival for CRP knockout pups subjected to neck, whereas the survival was only 65% for wild type pups.↗
▶Ep 94 · 4:18
clinicalMOP3 treatment reduced circulating eCIRP levels in NEC pups compared to vehicle↗
▶Ep 94 · 4:27
clinicalReduction in eCIRP with MOP3 treatment correlated with reduction in systemic inflammatory markers including IL-6 and TNF-alpha↗
▶Ep 94 · 4:37
clinicalMOP3 treatment protected against NEC severity with preservation of intestinal villi↗
▶Ep 94 · 4:55
clinicalMOP3 treatment reduced intestinal inflammation in NEC as measured by mRNA levels of IL-6 and TNF-alpha↗
▶Ep 94 · 5:05
clinicalMOP3-treated pups had significantly reduced fluorescence intensity indicating protection of the intestinal barrier compared to vehicle-treated NEC pups↗
▶Ep 94 · 5:22
quoteWhen we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.↗
▶Ep 94 · 5:22
clinicalMurine pups subjected to NEC and treated with MOP3 had 80% survival compared to only 50% survival in vehicle-treated pups↗
▶Ep 94 · 5:42
clinicaleCIRP exacerbates NEC pathogenesis by increasing inflammation and intestinal injury↗
▶Ep 94 · 5:42
clinicalMOP3 protects against NEC pathogenesis by scavenging eCIRP and preventing deleterious downstream impacts↗
▶Ep 94 · 6:53
clinicalMOP3 is effective in other models of ischemia-reperfusion injury in the gut↗
▶Ep 94 · 7:00
clinicalThe therapeutic benefit of MOP3 is not at the same level as complete CIRP knockdown↗
▶Ep 94 · 7:34
clinicalThe murine NEC model uses a 4-day protocol with continuous stressors including LPS, formula gavage, and hypoxia↗
▶Ep 94 · 7:49
clinicalMOP3 treatment was administered once per day at the beginning of the model, ongoing with the NEC insult↗
Colleen's statements about Necrotizing Enterocolitis26 statements
Dr. Colleen Nofi - Best of the Best in Pediatric Surgery 2025
▶Ep 19 · 0:39
quoteNecrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.↗
▶Ep 19 · 0:39
clinicalNecrotizing enterocolitis is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by complex pathways that are not completely understood↗
▶Ep 19 · 0:52
clinicalNEC has limited treatment options and an unacceptably high morbidity and mortality risk↗
▶Ep 19 · 1:06
clinicalUnder biologic conditions, CIRP is found inside the cell where it acts as an RNA chaperone protein↗
▶Ep 19 · 1:12
clinicalIn states of cellular stress such as sepsis, CIRP escapes outside the cell↗
▶Ep 19 · 1:19
quoteOnce released from the cell, CRP becomes extracellular CIRP or ECIRP, where it then acts as a damp by enhancing the release of cytokines and chemokines, and amplifying the inflammatory cascade.↗
▶Ep 19 · 1:19
clinicalOnce released from the cell, extracellular CIRP acts as a DAMP by enhancing the release of cytokines and chemokines and amplifying the inflammatory cascade↗
▶Ep 19 · 1:33
clinicalMOP3 (MFGE8 derived oligopeptide 3) is an eCIRP scavenging peptide that removes eCIRP from circulation to reduce inflammation↗
▶Ep 19 · 2:30
clinicalCIRP knockout protected pups from NEC severity with preservation of intestinal villi architecture↗
▶Ep 19 · 2:59
clinicalCIRP knockout mice subjected to NEC showed reduced intestinal inflammation as measured by mRNA levels of IL-6 and TNF-alpha in the small bowel↗
▶Ep 19 · 3:36
clinicalCIRP knockout pups had reduced fluorescent dextran leakage indicating preserved intestinal barrier function compared to wild-type NEC pups↗
▶Ep 19 · 3:57
clinicalCIRP knockout pups subjected to NEC had 100% survival whereas wild-type pups had only 65% survival in the same model under the same conditions↗
▶Ep 19 · 3:57
quoteRemarkably, in the same model under the same conditions, there was 100% survival for CRP knockout pups subjected to neck, whereas the survival was only 65% for wild type pups.↗
▶Ep 19 · 4:18
clinicalMOP3 treatment reduced circulating eCIRP levels in NEC pups compared to vehicle↗
▶Ep 19 · 4:27
clinicalReduction in eCIRP with MOP3 treatment correlated with reduction in systemic inflammatory markers including IL-6 and TNF-alpha↗
▶Ep 19 · 4:37
clinicalMOP3 treatment protected against NEC severity with preservation of intestinal villi↗
▶Ep 19 · 4:55
clinicalMOP3 treatment reduced intestinal inflammation in NEC as measured by mRNA levels of IL-6 and TNF-alpha↗
▶Ep 19 · 5:05
clinicalMOP3-treated pups had significantly reduced fluorescence intensity indicating protection of the intestinal barrier compared to vehicle-treated NEC pups↗
▶Ep 19 · 5:22
quoteWhen we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.↗
▶Ep 19 · 5:22
clinicalMurine pups subjected to NEC and treated with MOP3 had 80% survival compared to only 50% survival in vehicle-treated pups↗
▶Ep 19 · 5:42
clinicalMOP3 protects against NEC pathogenesis by scavenging eCIRP and preventing deleterious downstream impacts↗
▶Ep 19 · 5:42
clinicaleCIRP exacerbates NEC pathogenesis by increasing inflammation and intestinal injury↗
▶Ep 19 · 6:53
clinicalMOP3 is effective in other models of ischemia-reperfusion injury in the gut↗
▶Ep 19 · 7:00
clinicalThe therapeutic benefit of MOP3 is not at the same level as complete CIRP knockdown↗
▶Ep 19 · 7:34
clinicalThe murine NEC model uses a 4-day protocol with continuous stressors including LPS, formula gavage, and hypoxia↗
▶Ep 19 · 7:49
clinicalMOP3 treatment was administered once per day at the beginning of the model, ongoing with the NEC insult↗
Colleen's statements about Necrotizing Enterocolitis26 statements
Dr. Colleen Nofi - Best of the Best in Pediatric Surgery 2025
▶Ep 8 · 0:39
quoteNecrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.↗
▶Ep 8 · 0:39
clinicalNecrotizing enterocolitis is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by complex pathways that are not completely understood↗
▶Ep 8 · 0:52
clinicalNEC has limited treatment options and an unacceptably high morbidity and mortality risk↗
▶Ep 8 · 1:06
clinicalUnder biologic conditions, CIRP is found inside the cell where it acts as an RNA chaperone protein↗
▶Ep 8 · 1:12
clinicalIn states of cellular stress such as sepsis, CIRP escapes outside the cell↗
▶Ep 8 · 1:19
clinicalOnce released from the cell, extracellular CIRP acts as a DAMP by enhancing the release of cytokines and chemokines and amplifying the inflammatory cascade↗
▶Ep 8 · 1:19
quoteOnce released from the cell, CRP becomes extracellular CIRP or ECIRP, where it then acts as a damp by enhancing the release of cytokines and chemokines, and amplifying the inflammatory cascade.↗
▶Ep 8 · 1:33
clinicalMOP3 (MFGE8 derived oligopeptide 3) is an eCIRP scavenging peptide that removes eCIRP from circulation to reduce inflammation↗
▶Ep 8 · 2:30
clinicalCIRP knockout protected pups from NEC severity with preservation of intestinal villi architecture↗
▶Ep 8 · 2:59
clinicalCIRP knockout mice subjected to NEC showed reduced intestinal inflammation as measured by mRNA levels of IL-6 and TNF-alpha in the small bowel↗
▶Ep 8 · 3:36
clinicalCIRP knockout pups had reduced fluorescent dextran leakage indicating preserved intestinal barrier function compared to wild-type NEC pups↗
▶Ep 8 · 3:57
quoteRemarkably, in the same model under the same conditions, there was 100% survival for CRP knockout pups subjected to neck, whereas the survival was only 65% for wild type pups.↗
▶Ep 8 · 3:57
clinicalCIRP knockout pups subjected to NEC had 100% survival whereas wild-type pups had only 65% survival in the same model under the same conditions↗
▶Ep 8 · 4:18
clinicalMOP3 treatment reduced circulating eCIRP levels in NEC pups compared to vehicle↗
▶Ep 8 · 4:27
clinicalReduction in eCIRP with MOP3 treatment correlated with reduction in systemic inflammatory markers including IL-6 and TNF-alpha↗
▶Ep 8 · 4:37
clinicalMOP3 treatment protected against NEC severity with preservation of intestinal villi↗
▶Ep 8 · 4:55
clinicalMOP3 treatment reduced intestinal inflammation in NEC as measured by mRNA levels of IL-6 and TNF-alpha↗
▶Ep 8 · 5:05
clinicalMOP3-treated pups had significantly reduced fluorescence intensity indicating protection of the intestinal barrier compared to vehicle-treated NEC pups↗
▶Ep 8 · 5:22
clinicalMurine pups subjected to NEC and treated with MOP3 had 80% survival compared to only 50% survival in vehicle-treated pups↗
▶Ep 8 · 5:22
quoteWhen we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.↗
▶Ep 8 · 5:42
clinicaleCIRP exacerbates NEC pathogenesis by increasing inflammation and intestinal injury↗
▶Ep 8 · 5:42
clinicalMOP3 protects against NEC pathogenesis by scavenging eCIRP and preventing deleterious downstream impacts↗
▶Ep 8 · 6:53
clinicalMOP3 is effective in other models of ischemia-reperfusion injury in the gut↗
▶Ep 8 · 7:00
clinicalThe therapeutic benefit of MOP3 is not at the same level as complete CIRP knockdown↗
▶Ep 8 · 7:34
clinicalThe murine NEC model uses a 4-day protocol with continuous stressors including LPS, formula gavage, and hypoxia↗
▶Ep 8 · 7:49
clinicalMOP3 treatment was administered once per day at the beginning of the model, ongoing with the NEC insult↗
Colleen's statements about Necrotizing Enterocolitis26 statements
Dr. Colleen Nofi - Best of the Best in Pediatric Surgery 2025
▶Ep 24 · 0:39
quoteNecrotizing entercolitis or neck is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by a multitude of complex pathways that are not completely understood.↗
▶Ep 24 · 0:39
clinicalNecrotizing enterocolitis is a devastating gastrointestinal disease impacting premature infants whose pathophysiology is driven by complex pathways that are not completely understood↗
▶Ep 24 · 0:52
clinicalNEC has limited treatment options and an unacceptably high morbidity and mortality risk↗
▶Ep 24 · 1:06
clinicalUnder biologic conditions, CIRP is found inside the cell where it acts as an RNA chaperone protein↗
▶Ep 24 · 1:12
clinicalIn states of cellular stress such as sepsis, CIRP escapes outside the cell↗
▶Ep 24 · 1:19
quoteOnce released from the cell, CRP becomes extracellular CIRP or ECIRP, where it then acts as a damp by enhancing the release of cytokines and chemokines, and amplifying the inflammatory cascade.↗
▶Ep 24 · 1:19
clinicalOnce released from the cell, extracellular CIRP acts as a DAMP by enhancing the release of cytokines and chemokines and amplifying the inflammatory cascade↗
▶Ep 24 · 1:33
clinicalMOP3 (MFGE8 derived oligopeptide 3) is an eCIRP scavenging peptide that removes eCIRP from circulation to reduce inflammation↗
▶Ep 24 · 2:30
clinicalCIRP knockout protected pups from NEC severity with preservation of intestinal villi architecture↗
▶Ep 24 · 2:59
clinicalCIRP knockout mice subjected to NEC showed reduced intestinal inflammation as measured by mRNA levels of IL-6 and TNF-alpha in the small bowel↗
▶Ep 24 · 3:36
clinicalCIRP knockout pups had reduced fluorescent dextran leakage indicating preserved intestinal barrier function compared to wild-type NEC pups↗
▶Ep 24 · 3:57
clinicalCIRP knockout pups subjected to NEC had 100% survival whereas wild-type pups had only 65% survival in the same model under the same conditions↗
▶Ep 24 · 3:57
quoteRemarkably, in the same model under the same conditions, there was 100% survival for CRP knockout pups subjected to neck, whereas the survival was only 65% for wild type pups.↗
▶Ep 24 · 4:18
clinicalMOP3 treatment reduced circulating eCIRP levels in NEC pups compared to vehicle↗
▶Ep 24 · 4:27
clinicalReduction in eCIRP with MOP3 treatment correlated with reduction in systemic inflammatory markers including IL-6 and TNF-alpha↗
▶Ep 24 · 4:37
clinicalMOP3 treatment protected against NEC severity with preservation of intestinal villi↗
▶Ep 24 · 4:55
clinicalMOP3 treatment reduced intestinal inflammation in NEC as measured by mRNA levels of IL-6 and TNF-alpha↗
▶Ep 24 · 5:05
clinicalMOP3-treated pups had significantly reduced fluorescence intensity indicating protection of the intestinal barrier compared to vehicle-treated NEC pups↗
▶Ep 24 · 5:22
clinicalMurine pups subjected to NEC and treated with MOP3 had 80% survival compared to only 50% survival in vehicle-treated pups↗
▶Ep 24 · 5:22
quoteWhen we compared overall survival of murine pups subjected to the neck model, we found a significant improvement in survival, up to 80% in pups treated with MP3, compared to only 50% for vehicle treated pups.↗
▶Ep 24 · 5:42
clinicalMOP3 protects against NEC pathogenesis by scavenging eCIRP and preventing deleterious downstream impacts↗
▶Ep 24 · 5:42
clinicaleCIRP exacerbates NEC pathogenesis by increasing inflammation and intestinal injury↗
▶Ep 24 · 6:53
clinicalMOP3 is effective in other models of ischemia-reperfusion injury in the gut↗
▶Ep 24 · 7:00
clinicalThe therapeutic benefit of MOP3 is not at the same level as complete CIRP knockdown↗
▶Ep 24 · 7:34
clinicalThe murine NEC model uses a 4-day protocol with continuous stressors including LPS, formula gavage, and hypoxia↗
▶Ep 24 · 7:49
clinicalMOP3 treatment was administered once per day at the beginning of the model, ongoing with the NEC insult↗
